
Cytokeratin 17 Antibody E3 / KRT17 Epithelial Marker [clone E3] (V2176)

Catalog No.	Formulation	Size
V2176-100UG	0.2 mg/ml in 1X PBS with 0.1 mg/ml BSA (US sourced) and 0.05% sodium azide	100 ug
V2176-20UG	0.2 mg/ml in 1X PBS with 0.1 mg/ml BSA (US sourced) and 0.05% sodium azide	20 ug
V2176SAF-100UG	1 mg/ml in 1X PBS; BSA free, sodium azide free	100 ug
V2176IHC-7ML	Prediluted in 1X PBS with 0.1 mg/ml BSA (US sourced) and 0.05% sodium azide; *For IHC use only*	7 ml


Citations (10)

Bulk quote request


Species Reactivity	Human, Rat
Format	Purified
Host	Mouse
Clonality	Monoclonal (mouse origin)
Isotype	Mouse IgG2b, kappa
Clone Name	E3
Purity	Protein G affinity chromatography
Buffer	1X PBS, pH 7.4
UniProt	Q04695
RRID	AB_3756671
Localization	Cytoplasmic
Applications	Flow Cytometry : 1-2ug/million cells Immunofluorescence : 1-2ug/ml Western Blot : 1-2ug/ml Immunohistochemistry (FFPE) : 1-2ug/ml for 30 min at RT
Limitations	This Cytokeratin 17 Antibody E3 / KRT17 Epithelial Marker is available for research use only.




Cytokeratin 17 Antibody E3 in Human Cervical Carcinoma IHC. Immunohistochemistry staining of FFPE human cervical carcinoma tissue with Cytokeratin 17 Antibody clone E3. HIER was performed by boiling tissue sections in pH 9 10mM Tris with 1mM EDTA for 10-20 min followed by cooling at room temperature for 20 min. Strong brown cytoplasmic staining is present in malignant epithelial cells, with comparatively little staining in the surrounding stromal and inflammatory compartments. The selective tumor epithelial staining demonstrates detection of the KRT17 epithelial marker with the Keratin 17 Antibody.




Cytokeratin 17 Antibody E3 in Human Bladder Carcinoma IHC. Immunohistochemistry staining of FFPE human bladder carcinoma tissue with Cytokeratin 17 Antibody clone E3. HIER was performed by boiling tissue sections in pH 9 10mM Tris with 1mM EDTA for 10-20 min followed by cooling at room temperature for 20 min. Intense brown cytoplasmic staining is concentrated within the malignant epithelial compartment, contrasting with the relatively weak staining of the adjacent stromal tissue. This prominent epithelial localization supports detection of KRT17 with the Keratin 17 Antibody.




Cytokeratin 17 Antibody E3 Shows Tumor-Selective Bladder Carcinoma Staining IHC. Immunohistochemistry staining of FFPE human bladder carcinoma tissue with Cytokeratin 17 Antibody clone E3. Strong HRP-DAB brown cytoplasmic staining is visible throughout the malignant epithelial cells, while the adjacent stromal compartment shows minimal labeling. This independent field further demonstrates the strong epithelial tumor localization of the KRT17 epithelial marker and reinforces tissue detection with the Keratin 17 Antibody.



Cytokeratin 17 Antibody E3 in HeLa Cervical Cancer Cells WB. Western blot analysis of human HeLa cervical cancer cell lysate with Cytokeratin 17 Antibody clone E3. Lane 1: HeLa cell lysate. A strong, discrete immunoreactive band is detected at approximately 48 kDa, consistent with the expected molecular weight of KRT17. The predominance of the expected target band with little additional reactivity demonstrates recognition of endogenous Cytokeratin 17 in this cervical cancer cell model and supports western blot performance of the Keratin 17 Antibody.



Cytokeratin 17 Antibody E3 Detection of KRT17 in HeLa Cells WB. Western blot analysis of human HeLa cervical cancer cell lysate with Cytokeratin 17 Antibody clone E3. Lane 1: HeLa cell lysate. A prominent band is detected at approximately 48 kDa, corresponding closely to the predicted molecular weight of the Cytokeratin 17/KRT17 intermediate filament protein. The strong target-sized signal provides an independent western blot demonstration of endogenous KRT17 detection and reinforces the specificity profile of the Keratin 17 Antibody.



Purified Cytokeratin 17 Antibody E3 SDS-PAGE. SDS-PAGE analysis of 2 ug purified, BSA-free Cytokeratin 17 Antibody clone E3 under non-reducing (NR) and reducing (R) conditions. The non-reduced preparation contains predominantly intact immunoglobulin near 150 kDa, while reduction produces the expected antibody heavy and light chain components at approximately 50 kDa and 25 kDa. The electrophoretic profile supports the integrity and purity of the purified Keratin 17 Antibody preparation.

Description

Cytokeratin 17 Antibody E3 / KRT17 Epithelial Marker recognizes keratin 17 (KRT17), also known as cytokeratin 17, CK17 or K17, a type I intermediate filament protein expressed in selected epithelial cell populations. Keratin intermediate filaments are major components of the epithelial cytoskeleton, where they contribute to mechanical stability, cellular architecture and resistance to physical stress. KRT17 has a characteristic distribution in basal epithelial compartments and specialized epithelial structures, making it an important marker for studying epithelial identity, differentiation and tissue organization.

KRT17 forms intermediate filament networks through association with type II keratin partners, particularly keratin 5 and keratin 6. These cytoplasmic filament systems provide structural support while participating in dynamic changes associated with epithelial growth and differentiation. In normal tissues, Cytokeratin 17 is associated with selected basal and myoepithelial populations and with specialized structures such as hair follicles and other appendageal epithelia. Its comparatively restricted distribution makes the KRT17 Epithelial Marker useful for identifying particular epithelial populations and investigating lineage and differentiation.

Cytokeratin 17 expression is responsive to changes in epithelial cell state. KRT17 can be induced during wound healing, tissue regeneration and other conditions involving epithelial activation or hyperproliferation. Beyond its structural contribution to intermediate filaments, KRT17 has been linked to cellular processes involving growth, stress responses and inflammatory signaling. These properties have expanded interest in Cytokeratin 17 as a research target for understanding epithelial adaptation during tissue injury, remodeling and disease.

Altered KRT17 expression is particularly relevant to cancer biology. Cytokeratin 17 has been investigated in numerous epithelial malignancies and is frequently studied as a marker of basal or squamous differentiation. Its expression can help characterize phenotypically distinct tumor cell populations and is often evaluated alongside other cytokeratins and epithelial markers. KRT17 has also been investigated in relation to tumor cell proliferation, differentiation, invasion and disease progression, making a Cytokeratin 17 Antibody useful for research into changes in epithelial identity accompanying malignant transformation.

Clone E3 is a well-established mouse monoclonal antibody for Cytokeratin 17 research, with use reported in more than 75 publications. This extensive literature history spans studies of epithelial differentiation, keratin expression, tissue pathology and cancer biology, providing researchers with a substantial body of previous work involving the same antibody clone. The long-standing use of clone E3 is an important differentiator when selecting an antibody for KRT17 research because experimental findings can be considered alongside results reported across numerous independent studies. NSJ Bioreagents offers clone E3 for research into Cytokeratin 17 expression, epithelial biology and cancer-associated changes in keratin expression.

A Cytokeratin 17 Antibody provides a well-established research reagent for detecting KRT17 and investigating this intermediate filament protein in epithelial differentiation, tissue remodeling and cancer biology.

Researchers studying KRT17 expression, epithelial differentiation and tumor biology can explore additional reagents on our Cytokeratin 17 Antibody / KRT17 Epithelial Marker Antibody page.

Application Notes

The concentration stated for each application is a general starting point. Variations in protocols, secondaries and substrates may require the Cytokeratin 17 Antibody E3 / KRT17 Epithelial Marker to be titered up or down for optimal performance.

1. Staining of formalin-fixed tissues requires boiling tissue sections in pH 9 10mM Tris with 1mM EDTA for 10-20 min followed by cooling at RT for 20 minutes.
2. The prediluted format is supplied in a dropper bottle and is optimized for use in IHC. After epitope retrieval step (if required), drip mAb solution onto the tissue section and incubate at RT for 30 min.

Immunogen

The cytoskeletal fraction of rat colon epithelium was used as the immunogen for this Cytokeratin 17 Antibody E3.

Storage

Store the Cytokeratin 17 Antibody E3 at 2-8oC (with azide) or aliquot and store at -20oC or colder (without azide).

Alternate Names

CK17 antibody, Keratin 17 antibody, KRT17 antibody, Cytokeratin-17 antibody

References (2)

Copyright © NSJ Bioreagents. All rights reserved.